Neurofilament heavy chain-like messenger RNA and protein are present in benign prostate and down-regulated in prostatic carcinoma

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3532-3536

  Schleicher, Rosemary L ^a,b,e   Hunter, Stephen B ^b   Zhang, Ming ^b   Zheng, Ming ^b   Tan, Wenxiao ^b   Bandea, Claudiu I ^c   Fallon, Michael T ^a,b   Bostwick, David G ^d   Varma, Vijay A ^a,b,e  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d MAYO CLINIC   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUROFILAMENT PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA PROBE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROFILAMENT; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CARCINOMA; DNA FINGERPRINTING; DOWN-REGULATION; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEUROFILAMENT PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0030796195     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bookstein, R., and Allred, D. C. Recessive oncogenes. Cancer (Phila.), 71 (Suppl. 3): 1179-1186, 1993.
2. Isaacs, W. B. Molecular genetics of prostate cancer. Cancer Surv., 25: 357-379, 1995.
3. Peehl, D. M. Oncogenes in prostate cancer. Cancer (Phila.), 71: 1159-1164, 1993.
4. Fournier, G., Latil, A., Amyet, Y., Ahalain, J. H., Volant, A., Mangin, P., Floch, H. H., and Lidereau, R. Gene amplifications in advanced-stage human prostate cancer. Urol. Res., 22: 343-347, 1995.
5. Liang, P., and Pardee, A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (Washington DC), 257: 967-971, 1992.
6. Liang, P., Averboukh, L., and Pardee, A. B. Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization. Nucleic Acids Res., 21: 3269-3275, 1993.
7. Wang, F. L., Wang, Y., Wong, W. K., Liu, Y., Addivinola, F. J., Liang, P., Chen, L. B., Kantoff, P. W., and Pardee, A. B. Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res., 56: 3634-3637, 1996.
8. Sternberger, L. A., and Sternberger, N. H. Monoclonal antibodies distinguish phosphorylaled and nonphosphorylated forms of neurofilaments in situ. Proc. Natl. Acad. Sci. USA, 80: 6126-6130, 1983.
9. Lees, J. F., Shneidman, P. S., Skuntz, S. F., Carden, M. J., and Luzzarini, R. A. The structure and organization of the human heavy neurofilament suhunit (NF-H) and the gene encoding it. EMBO J., 7: 1947-1955, 1988.
10. Schleicher, R. L., Fallon, M. T., Austin, G. E., Zheng, M., Zhang, M., and Collins, D. C. N-Nitroso-N-metnylurea induction of prostate cancer in rats: intravenous versus intraprostatic administration. Prostate. 28: 32-13, 1996.
11. Lee, M. K., and Cleveland, D. W. Neurofilament function and dysfunction: involvement in axonal growth and neuronal disease. Curr. Opin. Cell Biol., 6: 34-40, 1994.
12. Starr, R., Xiao, J., and Monteiro, M. J. Production of monoclonal antibodies against neurofilament-associaied proteins: demonstration of association with neurofilaments by a coimmunoprecipitation method. J. Neurochem., 64: 1860-1867, 1995.
13. Gotow, T., Tanaka, T., Nakamura, Y., and Takeda, M. Dephosphorylution of the largest neurofilament subunit protein influences the structure of crossbridges in reassembled neurofitaments. J. Cell Sci., 107: 1949-1957, 1994.
14. Julien, J-P., and Grosveld, F. Structure and expression of neurofilament genes. In: R. D. Burgoyne (ed.), The Neuronal Cytoskeleton, pp. 215-231, New York: Wiley-Liss, 1991.
15. Saeger, R., Anisowicz, A., Neveu, M., Liang, P., and Sotiropoulou, G. Identification by differential display of α 6 integrin as a candidate tumor suppressor gene. FASEB J., 7: 964-970, 1993.
16. Blass, J. P., Sheu, K-F., Ko, L-w., Baneher, C. L., Wisniewski, H. M., Bouvier, M., Duffy, J. T., and Baker, A. C. Presence of low amounts of "neuronal" antigens in cultured human skin fibroblasis. J. Neurol. Sci., 107: 223-232, 1992.
17. Gorza, L., Schiaffino, S., and Vitadello, M. Heart conduction system: a neural crest derivative? Brain Res., 457: 360-366, 1988.
18. Gerharz, C. D., Moll, R., Ramp, U., Mellin, W., and Gabbert, H. E. Multidirectional differentiation in a newly established human epithelioid sarcoma cell line (GRU-1) with co-expression of vimentin, cytokeratins and neurofilament proteins. Int. J. Cancer, 45: 143-152, 1990.
19. Escurat, M., Djabali, K., Huc, C., Landon, F., Becourt, C., Boitard, C., Gros, F., and Portier, M. M. Origin of the β cells of the islets of Langerhans is further questioned by the expression of neuronal intermediate filament proteins. peripherin and NF-L. in the rat insulinoma RIN5F cell line. Dev. Neurosci., 13: 424-432, 1991.
20. Granger, B. L., and Lazarides, E. Expression of the major neurofilament subunit in chicken erythrocytes. Science (Washington DC), 221; 553-556, 1983.
21. Marx, A., Wilisch, A., Schultz, A., Greiner, A., Magi, B., Pallini, V., Schalke, B., Toyka, K., Nix, W., Kirchner, T., and Muller-Hermelink, H. K. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors, Implications for the pathogenesis of myasthenia gravis. Am. J. Pathol., 148: 1839-1850, 1996.
22. Sainio, K., Nonclercq, D., Saarma, M., Palgi, J., Saxen, L., and Sariola, H. Neuronal characteristics in embryonal renal stroma. Int. J. Dev. Biol., 38: 77-84, 1994.
23. di Sant' Agnese, P. A. Neuroendocrine differentiation in precursors of prostate cancer. Eur. Urol. 30: 185-190, 1996.
24. Paul, A. B., Grant, E. S., Habib, F. K. The expression and localisation of β-nerve growth factor (β-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Br. J. Cancer. 74: 1990-1996, 1996.
25. Sanson, M., Marineau, C., Desmaze, C., Lutchman, M., Ruttledge, M., Baron, C., Narod, S., Delattre, O., Lenoir, G., Thomas, G., Aurias, A., and Rouleau, G. A. Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Hum. Mol. Genet., 2: 1215-1220, 1993.
26. Watson, C. J., Gaunt, L., Evans, G., Patel, K., Harris, R., and Strachan, T. A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum. Mol. Genet., 6: 701-704, 1993.
27. Okamoto, M., Sasaki, M., Sugio, K., Iwama, T., Ikeuchi, T., Tonomura, A., Sasazuki, T., and Miyaki, M. Loss of constitutional heterozygosity in colon carcinoma from patients with familial polyposis coli. Nature (Lond.), 331: 273-277, 1988.
28. Chen, L. C., Kurisu, W., Ljung, B. M., Goldman, E. S., Monroe, D. 2nd, and Smith, H. S Heterogeneity for allelic loss in human breast cancer. J. Natl. Cancer Inst., 84: 506-510, 1992.